Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7UP8X)

• Drug Name: Pegfilgrastim Drug Info
• Synonyms: Neulasta; Neulasta (TN); Pegfilgrastim (INN)

Indication

Disease Entry	ICD 11	Status	REF
Central nervous system neoplasm		Approved	[1]
Hemoglobinopathy		Approved	[2]
Lymphoma	2A80-2A86	Approved	[3]
Malignant solid tumour	2C10-2F32	Approved	[4]
MALT lymphoma		Approved	[2]
Nodal marginal zone lymphoma	2A85.0	Approved	[2]
Non-small-cell lung cancer	2C25.Y	Approved	[5]
Plasma cell myeloma	2A83.1	Approved	[6]
Splenic marginal zone lymphoma		Approved	[2]
Thalassemia	3A50	Approved	[7]

• Therapeutic Class: Immunomodulatory Agents
• Cross-matching ID:
  PubChem CID: 70683024
  TTD Drug ID: DM7UP8X

Molecule-Related Drug Atlas

Drug(s) Targeting Granulocyte colony-stimulating factor receptor (G-CSF-R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tbo-Filgrastim	DML6OE7	Neutropenia	4B00.0	Approved	[9]
Peg-G-CSF	DMBKWAF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
BLZ-945	DMG1LVA	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[10]
SBC-014	DMG1VXR	Neutropenia	4B00.0	Phase 2	[11]
AX-200	DMTAEMB	Cardiovascular disease	BA00-BE2Z	Phase 2	[12]
MAXY-G34	DMWLIPJ	Neutropenia	4B00.0	Phase 2	[13]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[14]
AMG 820	DMB6Q19	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
MK-6302	DMZUA5C	Neutropenia	4B00.0	Phase 1	[16]
PLX-5622	DMK4PWM	Autoimmune diabetes	5A10	Phase 1	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Granulocyte colony-stimulating factor receptor (G-CSF-R)	TTC70AJ	CSF3R_HUMAN	Binder	[8]

References

• [1] Pegfilgrastim-induced hyperleukocytosis. Ann Pharmacother. 2007 Sep;41(9):1524-30.
• [2] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [3] Feasibility and efficacy of low-dose pegfilgrastim for CD34(+) cell mobilization in lymphoma. J Clin Apher. 2020 Sep;35(5):413-419.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6969).
• [5] Efficacy and safety of second-line therapy of docetaxel plus ramucirumab after first-line platinum-based chemotherapy plus immune checkpoint inhibitors in non-small cell lung cancer (SCORPION): a multicenter, open-label, single-arm, phase 2 trial. EClinicalMedicine. 2023 Nov 10;66:102303.
• [6] Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. Ann Hematol. 2023 Jul;102(7):1915-1925.
• [7] Evaluating the safety and effectiveness of PegaGen(?) (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study. Support Care Cancer. 2022 Oct;30(10):8151-8158.
• [8] Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8.
• [9] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [10] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719).
• [11] A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2.
• [12] Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7.
• [13] Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38.
• [14] National Cancer Institute Drug Dictionary (drug id 747694).
• [15] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [16] Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636.
• [17] Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med. 2012; 18(1): 519-527.